GleamWall
中文EN

ACET Adicet Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1720580 · Fiscal year ends 12/26

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY20.9%
TTM EPS YoY78.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-85.9%
ROA-67.5%
ROIC (approx.)-97.0%
Asset turnover—

Leverage & solvency

Liabilities / assets20.4%
Debt / equity0.00x
Current ratio6.09x
Interest coverage-1,038.62x

Cash quality & payout

Operating cash flow / net income0.88x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$99.13M$99.32M
SG&A expense$22.99M$28.29M
Operating income-$122.11M-$127.61M
Interest expense$36,000$4,000
Pretax income-$116.80M-$117.12M
Income tax$0$0
Net income-$116.80M-$117.12M
EBITDA-$115.73M-$121.15M
EPS (basic)-16.95-21.33
EPS (diluted)-16.95-21.33
Weighted avg. shares (diluted)6.89M5.49M
Balance sheet
Cash & equivalents$38.92M$59.40M
Current assets$160.93M$180.14M
PP&E, net$16.53M$22.52M
Total assets$192.35M$220.22M
Current liabilities$21.53M$19.39M
Total liabilities$33.15M$33.61M
Shareholders' equity$159.21M$186.61M
Shares outstanding9.59M5.16M
Cash flow statement
Operating cash flow-$95.25M-$92.38M
Capital expenditure$1.74M$1.12M
Free cash flow-$96.98M-$93.50M
Investing cash flow$2.39M-$119.24M
Financing cash flow$75.25M$111.31M
Depreciation & amortization$6.38M$6.47M
Stock-based compensation$14.27M$22.23M

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.